Short answer
Stoke Therapeutics, Inc. (STOK) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $11M (up 5.9% year over year) with net income of −$74M.
Q3 2026 key financials · XBRL
- Revenue
- $11M
- +5.9% YoY · +20.7% QoQ
- Net income
- −$74M
- −92.0% YoY · −19.5% QoQ
- Operating margin
- -687.0%
- EPS (diluted)
- −$1.08
- −66.2% YoY · −14.9% QoQ
Source: XBRL data from the Stoke Therapeutics, Inc. (STOK) Q3 2026 10-Q on SEC EDGAR. USD.
Stoke Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $11.3M, up $0.7M YoY from $10.6M, driven by Acadia and Biogen collaborations
- Operating margin (77,315 ÷ 11,255) not disclosed as a percentage, versus (43,091 ÷ 10,632) not disclosed
- Best-performing program: zorevunersen R&D $28.7M vs $19.0M; ADOA $3.6M vs $1.6M
- Cash, equivalents and marketable securities $358.8M vs $390.9M at December 31, 2025; operations funded into early 2028
- Operating cash flow $(179.9)M vs $76.0M; financing provided $156.4M, including $146.4M from equity offering
Risk Factors
- Newly added regulatory risk: FDA staffing reductions and funding constraints could delay reviews, guidance and approvals under the current administration
- Most materially updated pricing risk: finalized 2026 GLOBE Model begins January 1, 2027, potentially reducing Medicare Part B drug prices
- Clinical risk: STK-002 entered its OSPREY Phase 1 study after first-patient dosing in February 2026
- Near-term operational risk: EMPEROR Phase 3 execution depends on hospital staffing and patient enrollment, despite first dosing in August 2025
- Liquidity risk: $358.8 million cash, equivalents and marketable securities expected to fund operations into early 2028
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Stoke Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.